CHSJ

Curr Health Sci J, vol. 46, no. 3, 2020

Strong Long-Term Survival with Targeted Therapy in Inoperable/Metastatic Gastrointestinal Stromal Tumors

[Case Report]

C. TUTA(1), B.I. VATU(2), S.A. ARTENE(3)


(1)Emergency County Hospital of Alexandria, Romania,
(2)Emergency County Hospital of Slatina, Romania,
(3)Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

Gastrointestinal stromal tumors (GISTs) belong to a group of cancers called soft-tissue sarcomas. Soft-tissue sarcomas develop in the tissues that support and connect the body, including muscles, nerves, tendons and joints. In this paper we report a case of 67-years old man with unresectable GIST and associated liver metastasis who experienced a very good response to Imatinib mesylate (Glivec®) therapy in first line for over 10 years. Even after progression and discovery of liver metastasis, increasing the Glivec® dose proved to be an efficient strategy with no added toxicity and an overall satisfactory quality of life.


Keywords: GIST, Imatinib, targeted therapy, metastasis.



Corresponding: Cristian Tuta, Emergency County Hospital of Alexandria, Romania, e-mail: tutacristi@yahoo.com


DOI 10.12865/CHSJ.46.03.16 - Download PDF
current issue cover Download cover
Download contents

Journal archive